Opposing Viewpoints10 Mar 2020 14:03
It is very clear from reading through the posts today that there are a number of posters who have expressed viewpoints largely contrary to those expressed repeatedly by key members of the Action Group. These comments should be recognised and appreciated.
1. It is clear that VAL will survive as an entity if the resolutions are approved and that equity finance can be arranged.
2. Without an equity finance raising- this company is essentially finished for existing shareholders. It will either go Into administration or other such process. The outcome of this is uncertain but it seems unlikely to be beneficial for shareholders.
3. The company have we assumed looked into alternative sources of finance but without success.
4. Equity finance is all to typical for early stage biotechs as other posters have highlighted so itās risky and dilution inevitable.
5. The product(s) are still at an early stage of development and outside partners or investors not yet ready convinced etc to take a stake.
We are now between a rock and a hard place to paraphrase statements made by other posters. I feel we have to step up discussions with the BOD and seek further clarifications around (a) current progress Val 201 and timeframes (b)cost control measures etc and (c) equity purchases by BOD.
Letās put some pressure on them to answer a,b, c above and allow us to be better informed on the vote.
We have made an impact but as one poster mentioned - we also backed them into a corner somewhat. Itās a risky enough bargaining decision. If pushed too far people will fight rather than flight.
Suggest we regroup rethink and refocus. All us not lost- as one poster so eloquently put it - do we want a % of something or a 100% of nothing. I know what I want!